{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T09:12:35Z","timestamp":1788599555482,"version":"build-2803163510"},"reference-count":28,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82073708"],"award-info":[{"award-number":["82073708"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic & Medicinal Chemistry"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.bmc.2026.118758","type":"journal-article","created":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T23:28:12Z","timestamp":1785281292000},"page":"118758","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["A highly selective 1,2-dihydroquinoxaline derivative as a potent PRMT5-MTA complex inhibitor"],"prefix":"10.1016","volume":"142","author":[{"given":"Yiru","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhihao","family":"Jiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daoguang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoxi","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongjun","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guisen","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bmc.2026.118758_bb0005","doi-asserted-by":"crossref","first-page":"2917","DOI":"10.1007\/s00018-019-03145-x","article-title":"Protein arginine methyltransferases: insights into the enzyme structure and mechanism at the atomic level","volume":"76","author":"Tewary","year":"2019","journal-title":"Cell Mol Life Sci"},{"key":"10.1016\/j.bmc.2026.118758_bb0010","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1038\/s12276-021-00613-y","article-title":"Protein arginine methyltransferases: promising targets for cancer therapy","volume":"53","author":"Hwang","year":"2021","journal-title":"Exp Mol Med"},{"key":"10.1016\/j.bmc.2026.118758_bb0015","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.3390\/life11101074","article-title":"The structure and functions of PRMT5 in human diseases","volume":"11","author":"Motolani","year":"2021","journal-title":"Life"},{"key":"10.1016\/j.bmc.2026.118758_bb0020","doi-asserted-by":"crossref","first-page":"2041","DOI":"10.1007\/s00018-015-1847-9","article-title":"The PRMT5 arginine methyltransferase: many roles in development, cancer and beyond","volume":"72","author":"Stopa","year":"2015","journal-title":"Cell Mol Life Sci"},{"key":"10.1016\/j.bmc.2026.118758_bb0025","doi-asserted-by":"crossref","first-page":"1596","DOI":"10.1021\/jm501234a","article-title":"Selective inhibitors of protein methyltransferases","volume":"58","author":"Kaniskan","year":"2014","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2026.118758_bb0030","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2022.114842","article-title":"Medicinal chemistry strategies targeting PRMT5 for cancer therapy","volume":"244","author":"Fu","year":"2022","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.bmc.2026.118758_bb0035","first-page":"2081","article-title":"Targeting protein arginine methyltransferase 5 in disease, future","volume":"9","author":"Richters","year":"2017","journal-title":"Med Chem"},{"key":"10.1016\/j.bmc.2026.118758_bb0040","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2024.107859","article-title":"Medicinal chemistry insights into PRMT5 inhibitors","volume":"153","author":"Jiao","year":"2024","journal-title":"Bioorg Chem"},{"key":"10.1016\/j.bmc.2026.118758_bb0045","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2021.112252","article-title":"Targeting protein arginine methyltransferase 5 in cancers: roles, inhibitors and mechanisms","volume":"144","author":"Chen","year":"2021","journal-title":"Biomed Pharmacother"},{"key":"10.1016\/j.bmc.2026.118758_bb0050","doi-asserted-by":"crossref","first-page":"870","DOI":"10.3389\/fphys.2017.00870","article-title":"Regulation of skeletal muscle plasticity by protein arginine methyltransferases and their potential roles in neuromuscular disorders","volume":"8","author":"Stouth","year":"2017","journal-title":"Front Physiol"},{"key":"10.1016\/j.bmc.2026.118758_bb0055","doi-asserted-by":"crossref","first-page":"2933","DOI":"10.1007\/s00018-019-03140-2","article-title":"Cellular consequences of arginine methylation","volume":"76","author":"Lorton","year":"2019","journal-title":"Cell Mol Life Sci"},{"key":"10.1016\/j.bmc.2026.118758_bb0060","doi-asserted-by":"crossref","first-page":"6262","DOI":"10.1128\/MCB.00923-08","article-title":"Protein arginine methyltransferase 5 suppresses the transcription of the RB family of tumor suppressors in Leukemia and lymphoma cells","volume":"28","author":"Wang","year":"2023","journal-title":"Mol Cell Biol"},{"key":"10.1016\/j.bmc.2026.118758_bb0065","doi-asserted-by":"crossref","first-page":"2321","DOI":"10.1177\/1010428317695917","article-title":"Elevated expression of protein arginine methyltransferase 5 predicts the poor prognosis of breast cancer","volume":"39","author":"Wu","year":"2017","journal-title":"Tumour Biol"},{"key":"10.1016\/j.bmc.2026.118758_bb0070","doi-asserted-by":"crossref","first-page":"3684","DOI":"10.3390\/ijms21103684","article-title":"Regulation of a PRMT5\/NF-\u03baB Axis by phosphorylation of PRMT5 at serine 15 in colorectal Cancer","volume":"21","author":"Hartley","year":"2020","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.bmc.2026.118758_bb0075","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1126\/science.aad5214","article-title":"MTAP deletion confers enhanced dependency on the PRMT5 arginine methyltransferase in cancer cells","volume":"351","author":"Kryukov","year":"2016","journal-title":"Science"},{"key":"10.1016\/j.bmc.2026.118758_bb0080","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1038\/modpathol.2009.186","article-title":"CDKN2A and MTAP deletions in peritoneal mesotheliomas are correlated with loss of p16 protein expression and poor survival","volume":"23","author":"Krasinskas","year":"2010","journal-title":"Mod Pathol"},{"key":"10.1016\/j.bmc.2026.118758_bb0085","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1038\/s41573-019-0046-z","article-title":"Synthetic lethality as an engine for cancer drug target discovery","volume":"19","author":"Huang","year":"2019","journal-title":"Nat Rev Drug Discov"},{"issue":"1","key":"10.1016\/j.bmc.2026.118758_bb0090","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1093\/genetics\/59.1.37","article-title":"Synthetic lethality and semi-lethality among functionally related mutants of Drosophila melanfgaster","volume":"59","author":"C.","year":"1968","journal-title":"Genetics"},{"key":"10.1016\/j.bmc.2026.118758_bb0095","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1016\/j.celrep.2016.03.043","article-title":"MTAP deletions in Cancer create vulnerability to targeting of the MAT2A\/PRMT5\/RIOK1 Axis","volume":"15","author":"Marjon","year":"2016","journal-title":"Cell Rep"},{"key":"10.1016\/j.bmc.2026.118758_bb0100","doi-asserted-by":"crossref","unstructured":"M.E.R. Mavrakis K J, 3rd, Schlabach M R, et al., Disordered methionine metabolism in MTAP\/CDKN2A-deleted cancers leads to dependence on PRMT5, Science, 351 (2016) 1208\u20131213.","DOI":"10.1126\/science.aad5944"},{"key":"10.1016\/j.bmc.2026.118758_bb0105","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1136\/jitc-2024-009600","article-title":"MTA-cooperative PRMT5 inhibitors enhance T cell-mediated antitumor activity in MTAP-loss tumors","volume":"12","author":"Chen","year":"2024","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.bmc.2026.118758_bb0110","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1021\/acsmedchemlett.5b00380","article-title":"Structure and property guided Design in the Identification of PRMT5 tool compound EPZ015666","volume":"7","author":"Duncan","year":"2015","journal-title":"ACS Med Chem Lett"},{"key":"10.1016\/j.bmc.2026.118758_bb0115","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1021\/acs.jmedchem.1c01900","article-title":"Fragment-based discovery of MRTX1719, a synthetic lethal inhibitor of the PRMT5\u2022MTA complex for the treatment of MTAP-deleted cancers","volume":"65","author":"Smith","year":"2022","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2026.118758_bb0120","doi-asserted-by":"crossref","first-page":"6064","DOI":"10.1021\/acs.jmedchem.4c00133","article-title":"Discovery of TNG908: a selective, brain penetrant, MTACooperative PRMT5 inhibitor that is synthetically lethal with MTAPDeleted cancers","volume":"67","author":"Cottrell","year":"2024","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2026.118758_bb0125","doi-asserted-by":"crossref","first-page":"6932","DOI":"10.1021\/acs.jmedchem.4c03121","article-title":"Discovery of AMG 193, an MTA-cooperative PRMT5 inhibitor for the treatment of MTAP-deleted cancers","volume":"68","author":"Pettus","year":"2025","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2026.118758_bb0130","doi-asserted-by":"crossref","first-page":"2412","DOI":"10.1158\/2159-8290.CD-23-0669","article-title":"MRTX1719 is an MTA-cooperative PRMT5 inhibitor that exhibits synthetic lethality in preclinical models and patients with MTAP-deleted Cancer","volume":"13","author":"Engstrom","year":"2023","journal-title":"Cancer Discov"},{"key":"10.1016\/j.bmc.2026.118758_bb0135","doi-asserted-by":"crossref","DOI":"10.1016\/j.tranon.2024.102264","article-title":"TNG908 is a brain-penetrant, MTA-cooperative PRMT5 inhibitor developed for the treatment of MTAP-deleted cancers","volume":"52","author":"Briggs","year":"2025","journal-title":"Transl Oncol"},{"key":"10.1016\/j.bmc.2026.118758_bb0140","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1016\/j.annonc.2024.08.2339","article-title":"First-in-human study of AMG 193, an MTA-cooperative PRMT5 inhibitor, in patients with MTAP-deleted solid tumors: results from phase I dose exploration","volume":"35","author":"Rodon","year":"2024","journal-title":"Ann Oncol."}],"container-title":["Bioorganic & Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0968089626002142?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0968089626002142?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T08:37:53Z","timestamp":1788597473000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0968089626002142"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":28,"alternative-id":["S0968089626002142"],"URL":"https:\/\/doi.org\/10.1016\/j.bmc.2026.118758","relation":{},"ISSN":["0968-0896"],"issn-type":[{"value":"0968-0896","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A highly selective 1,2-dihydroquinoxaline derivative as a potent PRMT5-MTA complex inhibitor","name":"articletitle","label":"Article Title"},{"value":"Bioorganic & Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bmc.2026.118758","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"118758"}}